Evidence map›Paper›PMID 30100992›Full record

ArticleOncotarget2018

Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrain").

Jeriel T R Keeney, Xiaojia Ren, Govind Warrier, Teresa Noel, David K Powell, Jennifer M Brelsfoard, Rukhsana Sultana, Kathryn E Saatman, Daret K St Clair, D Allan Butterfield

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jeriel T R KeeneyDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Xiaojia RenDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Govind WarrierDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Teresa NoelDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.
David K PowellMagnetic Resonance Imaging and Spectroscopy Center, University of Kentucky Medical Center, Lexington, KY 40536, USA.
Jennifer M BrelsfoardSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY 40536, USA.
Rukhsana SultanaDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Kathryn E SaatmanSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY 40536, USA.
Daret K St ClairDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.
D Allan ButterfieldDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
University of Kentucky · USMarkey Cancer Center · US

Funding

UK Spinal Cord &Brain Injury Research Center Core GrantP30NS051220 · NINDS · UNIVERSITY OF KENTUCKY · PI HALL, EDWARD D. · 2005 to 2015
$6.4M
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairmentR01CA217934 · NCI · UNIVERSITY OF KENTUCKY · PI BONDADA, SUBBARAO, BUTTERFIELD, D. ALLAN · 2017 to 2021
$2.7M
NCI NIH HHS R01 CA217934NINDS NIH HHS P30 NS051220
6 · The paper itself

Abstract

Chemotherapy-induced cognitive impairment (CICI) is now widely recognized as a real and too common complication of cancer chemotherapy experienced by an ever-growing number of cancer survivors. Previously, we reported that doxorubicin (Dox), a prototypical reactive oxygen species (ROS)-producing anti-cancer drug, results in oxidation of plasma proteins, including apolipoprotein A-I (ApoA-I) leading to tumor necrosis factor-alpha (TNF-α)-mediated oxidative stress in plasma and brain. We also reported that co-administration of the antioxidant drug, 2-mercaptoethane sulfonate sodium (MESNA), prevents Dox-induced protein oxidation and subsequent TNF-α elevation in plasma. In this study, we measured oxidative stress in both brain and plasma of Dox-treated mice both with and without MESNA. MESNA ameliorated Dox-induced oxidative protein damage in plasma, confirming our prior studies, and in a new finding led to decreased oxidative stress in brain. This study also provides further functional and biochemical evidence of the mechanisms of CICI. Using novel object recognition (NOR), we demonstrated the Dox administration resulted in memory deficits, an effect that was rescued by MESNA. Using hydrogen magnetic resonance imaging spectroscopy (H

Indexed as

chemotherapy induced cognitive impairmentcholinecognitive dysfunctionoxidative stress

Identifiers

PMID30100992
PMCPMC6084398
OpenAlexW2883872827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.